Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	30.67B -7.0%
Revenue (ttm)	3.70B +31.2%
Net Income	1.04B +25.4%
EPS	2.55 +25.6%
Shares Out	408.19M
PE Ratio	29.46
Forward PE	20.99
Dividend	0.62 (0.82%)
Ex-Dividend Date	May 9, 2025

Volume	1,242,279
Average Volume	2,335,351
Open	75.58
Previous Close	75.65
Day's Range	74.47 - 76.00
52-Week Range	67.96 - 93.52
Beta	-0.17
RSI	51.02
Earnings Date	Mar 27, 2026

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, such as pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 2,685
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2025, Xiamen Amoytop Biotech's revenue was 3.70 billion, an increase of 31.18% compared to the previous year's 2.82 billion. Earnings were 1.04 billion, an increase of 25.39%.